October 10, 2024--GoodRx Holdings, Inc. (Nasdaq: GDRX ... GoodRx announced a new partnership with Boehringer Ingelheim to provide discounts for a biosimilar to rheumatoid arthritis drug Humira ...
The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...
The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.
Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...
Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific ...
An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...
Paige Mahaney, Ph.D. Chief Scientific Officer Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience ...
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will ...
The major players in the market are Inflarx, Novartis Pharmaceuticals ... Boehringer Ingelheim, Eli Lilly, Moonlake ...
In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback